Luteal blood flow as a predictive factor for methotrexate treatment outcomes in women with unruptured tubal pregnancy

Table 2 Dose and side effects of MTX treatment

Variable	Poor blood flow group (n = 56)	Abundant blood flow group (n = 59)	P-value^a
Success rate of MTX treatment			0.034
One dose	55 (98.2)	52 (88.1)
Second dose ^b	1 (1.8)	7 (11.9)
Side effects of MTX	8 (14.3)	11 (18.6)	0.529
Clinical symptoms
Nausea	3 (5.4)	5 (8.5)
Diarrhoea	2 (3.6)	2 (3.4)
Laboratory results
Rise of ALT	2 (3.6)	3 (5.1)
Rise of AST	1 (1.8)	1 (1.7)

Values are presented as number (percentage)
ALT alanine aminotransferase, AST aspartate transarninase
^aChi-square test or Fisher’s exact test
^bSecond dose was given if serum β-hCG level did not decline 15% between days 4 and 7

ISSN: 1471-2393